Merck facts and figures. This document provides key information on the pharmaceutical player Merck. It covers financials, strategic aspects and other KPI's as well as information on corporate responsibility topics.

1. The MERCK GRoup
AN OVERVIEW
3_013_FACTS+FIGURES_EN.indd 1
13.03.13 15:0

2. OUR FIELDS:
PHARMACEUTICALS. CHEMICALS. LIFE SCIENCE.
At Merck, around 39,000 people in 66 countries develop pharmaceutical, chemical and life science innovations. We operate our businesses in four divisions:
Merck Serono, Consumer Health, Performance Materials and Merck Millipore.
PHARMACEUTICALS: We discover, develop, manufacture and commercialize
innovative prescription drugs and therapies for high unmet medical needs.
Through their targeted effect, these help patients to live a longer and better
life (Merck Serono).
In addition, for the consumer health care market, we offer a wide range
of over-the-counter products that help prevent illness and relieve minor
complaints (Consumer Health).
3_013_FACTS+FIGURES_EN.indd 2
13.03.13 15:0

3. CE.
CHEMICALS: Our broad range of specialty chemicals are used in
t
­echnologically sophisticated applications ranging from liquid crystal
mixtures for flat-panel displays, to effect pigments and cosmetic
­ingredients (Performance Materials).
LIFE SCIENCE: As a leading global partner to this future-oriented industry,
we offer products, applications and solutions for protein research and
cell biology as well as for the manufacture of chemical and biopharmaceutical drugs. Our products and services range from laboratory chemir
cals, ­ eagents and consumables to analytical methods and laboratory
p
water ­ urification systems (Merck Millipore).
3_013_FACTS+FIGURES_EN.indd 3
13.03.13 15:0

4. OUR STRATEGY:
PROFITABLE GROWTH.
3_013_FACTS+FIGURES_EN.indd 4
13.03.13 15:0

5. We are convinced that in our core pharmaceutical, chemical and life science
businesses, the market will reward successful research and technological
a
­ dvances with attractive margins. Our focus is on innovative specialty products. Competing on price alone and operating in commodity markets is not
what we do.
We have a clear objective: profitable growth. This is based on a distinct,
fundamental strategy that can be summed up in three words: Sustain.
Change. Grow. It’s a strategy based on the right balance between the old
and the new, between tradition and innovation. It gives us the best possible
preconditions for future growth and makes it possible to fully unleash our
entrepreneurial potential.
Our strategy and our ethical company values give our employees clear
o
­ rientation for their daily work. We enable them to share in the company’s
success and, thus, also in the execution risk. This way, we will remain
c
­ urious and courageous – and continue to seize many new opportunities
in the future.
3_013_FACTS+FIGURES_EN.indd 5
13.03.13 15:0

6. KEY ProDUCTs:
Multiple Sclerosis: Rebif®
Oncology:
Erbitux® (solid tumors)
Fertility:
Gonal-f®, Pergoveris™, Luveris®, Ovidrel®/Ovitrelle®,
Crinone®, Cetrotide® (infertility treatment)
3_013_FACTS+FIGURES_EN.indd 6
13.03.13 15:0

7. MERCK SERONO:
EFFECTIVE MEDICINES TO FIGHT
DAUNTING OPPONENTS.
Merck Serono is the largest division of Merck and focuses on specialist
t
­herapeutic areas such as oncology, multiple sclerosis, growth disorders,
and infertility. The division offers innovative prescription drugs of chemical
and biological origin.
We are proud of our innovative products – and we invest around € 1 billion
in R&D every year in our core therapeutic areas Oncology, Multiple Sclerosis
and Immunology.
Endocrinology:
General Medicine:
3_013_FACTS+FIGURES_EN.indd 7
Saizen® (growth hormone disorders),
Serostim® (HIV-associated wasting),
Kuvan® (metabolic disorder hyperphenylalaninemia),
Egrifta™ (HIV-associated lipodystrophy)
Glucophage® franchise (type 2 diabetes),
Concor® franchise (cardiovascular diseases),
Euthyrox® (thyroid disorders)
13.03.13 15:0

8. KEY ProDUCTS:
Mobility:
Products to strengthen the joints and relieve pain, including the brands
Seven Seas® and Kytta®
Cough and cold:
Cold treatment Nasivin® (Iliadin®); Sedalmerck® for pain relief
3_013_FACTS+FIGURES_EN.indd 8
13.03.13 15:0

9. CONSUMER HEALTH:
PREVENTING MINOR AILMENTS
AND PROTECTING HEALTH.
Many consumers around the world trust a wide range of well-known brands
with scientifically based mechanisms of action that Merck develops, manufactures and markets for the OTC (over-the-counter) pharmaceutical sector. Our focus in the Consumer Health division is on eight strategic brands,
specializing in key aspects of health care, such as mobility, everyday health
protection, women’s health, cough and cold, and allergies. Our scientifically
based product portfolio is aligned to the needs of consumers worldwide.The
main distribution channels are pharmacies, as well as retail chains, drugstores
and mail order in some countries.
Everyday health protection:
Probiotic multivitamin products from the Bion® and Multibionta® ranges
Vitamins and minerals sold under brand names such as Cebion® and Diabion®
Women’s and children’s health:
Femibion®, products with folic acid and Metafolin® for pregnant and
nursing women; Kidabion® (Haliborange®), a vitamin product range for
c
­ hildren; Sangobion® for iron deficiency
3_013_FACTS+FIGURES_EN.indd 9
13.03.13 15:0

10. KEY ProDUCTS:
licristal® Liquid crystal mixtures for displays
Isiphor® Lighting materials for energy-efficient, high-quality LED lighting
livilux®
Materials for OLEDs (organic light-emitting diodes)
isishape®
Efficient, eco-friendly materials for structuring solar cells and
touchscreens
3_013_FACTS+FIGURES_EN.indd 10
13.03.13 15:0

11. PERFORMANCE MATERIALS:
LCDs, EFFECT PIGMENTS AND MORE.
Merck is the global leader in the liquid crystals market. Liquid crystals are
used throughout the world, in LCD TVs, monitors, tablet computers, notebooks,
and mobile phones. In addition, the Performance Materials division focuses
on materials for energy-saving lighting using LEDs (light-emitting diodes) and
OLEDs (organic LEDs) as well as for OLED smartphone displays.
Pigments for the coatings, plastics and printing industries as well as for
c
­ osmetic applications are an important part of the Performance Materials
portfolio. Moreover, the division is the market leader for pearl luster effect
p
­ igments – a highly specialized niche within the pigment market.
Iriodin®, Xirallic ®, Colorstream ®
Effect pigments for use in coatings, packaging and product design
Timiron®, Colorona®, Ronaflair ®, Xirona®
Effect and functional pigments for cosmetic formulations
Ronacare®
Cosmetic active ingredients for skin care
3_013_FACTS+FIGURES_EN.indd 11
13.03.13 15:0

12. KEY ProDUCTS:
Products for life science research in the pharmaceutical and biotechnology
industries
Products for protein research and cell biology including consumables,
reagents and services to help customers better understand diseases and
biological functions
3_013_FACTS+FIGURES_EN.indd 12
13.03.13 15:0

13. MERCK MILLIPORE:
PRODUCTS AND SERVICES FOR PHARMACEUTICAL RESEARCH AND BIOTECHNOLOGY.
With the Merck Millipore division, Merck is a leading life science tools
c
­ ompany. The portfolio comprises products and services for the life science
industry such as assays, biomarkers and target solutions, as well as bioprocessing, lab water purification and filtration. These are used by customers
working in research and analytical laboratories as well as in pharmaceutical
manufacturing. Additionally, the division supplies specialty chemicals mainly
to regulated markets, for example the pharmaceutical, cosmetics and food
industries. Analytical and scientific laboratories use the reagents and test kits
supplied by the division. The Merck Millipore portfolio comprises more than
60,000 products and processes.
Laboratory chemicals and materials for research, science and industry
Products and services for sampling and assay platforms for the pharmaceutical,
food and diagnostics industries
Products, consumables and services for ultrapure laboratory water in science
and industry
Products that help to develop and manufacture pharmaceutical and biopharmaceutical drugs safely and efficiently
3_013_FACTS+FIGURES_EN.indd 13
13.03.13 15:0

14. OUR INNOVATIONS:
GOOD NEWS.
3_013_FACTS+FIGURES_EN.indd 14
13.03.13 15:0

15. • Extended indication of the multiple sclerosis drug Rebif® was approved
in Europe in 2012 for use in patients who have experienced a single
demyelinating event, an early sign of the disease.
• The targeted oncology drug Erbitux® is currently approved for use in colorectal cancer in 92 countries and in head and neck cancer in 90 countries.
• Merck Serono researchers are currently working on 16 projects in
drug development.
• With innovative liquid crystal mixtures for polymer-stabilized vertical
alignment (PS-VA) applications, we further expanded our technology leadership. PS-VA technology opens up new possibilities for LCD producers to
achieve previously unattained screen properties.
• Organic light-emitting diodes (OLEDs) convert electricity most efficiently
into light and can be produced as thin, flexible films. Application possibilities
include displays, for example in mobile phones or small televisions.
• With Scepter™, the Merck Millipore division launched the world’s first automated handheld cell counter.
• For photovoltaics, Merck supplies materials for the cost-efficient production
of solar cells and develops new materials, e.g. for flexible, organic solar cells.
• Merck is working on innovative lighting materials, such as those for
p
­ ower-saving white LEDs, which may represent an alternative to conventional
incandescent light bulbs and energy-saving lamps.
3_013_FACTS+FIGURES_EN.indd 15
13.03.13 15:0

16. MERCK MANAGEMENT:
THE MEMBERS OF THE EXECUTIVE BOARD.
3_013_FACTS+FIGURES_EN.indd 16
Karl-Ludwig Kley, Chairman
Born in 1951, lawyer
Member of the Merck Supervisory Board and Board of Partners
from March 2004 to June 2006; on the Merck Executive Board
since September 2006.
Responsible for Group functions:
Group Strategy, Group Communications, Group Legal
and Compliance, Group Internal Auditing
Kai Beckmann, Head of Human Resources /
Chief Administration Officer
Born in 1965, university degree in computer science
Joined Merck in 1989; on the Merck Executive Board
since April 2011.
Responsible for Group functions:
Group Human Resources, Group Information Services,
Site Operations, Inhouse Consulting
Stefan Oschmann,
responsible for the Merck Serono
and Consumer Health divisions
Born in 1957, veterinarian
On the Merck Executive Board since January 2011.
Responsible for Group functions:
Patents Scientific Services
13.03.13 15:0

17. 3_013_FACTS+FIGURES_EN.indd 17
Bernd Reckmann,
responsible for the Performance Materials
and Merck Millipore divisions
Born in 1955, biochemist
Joined Merck in 1986; on the Merck Executive Board
since January 2007.
Responsible for Group functions:
Environment, Health, Safety, Security, Quality
Matthias Zachert, Chief Financial Officer
Born in 1967, university degree in business
On the Merck Executive Board since June 2011.
Responsible for Group functions:
Group Accounting Subsidiaries, Group Controlling Risk
Management, Corporate Finance, Group Tax, Group Insurance,
Group Procurement, Investor Relations
13.03.13 15:0

18. MERCK AT A GLANCE:
KEY FIGURES FOR 2012.
In 2012, the Merck Group generated total revenues of € 11.2 billion.
The Merck Serono division accounted for € 6.4 billion, the Consumer Health
division for € 475 million, the Performance Materials division for € 1.7 billion
and the Merck Millipore division for € 2.6 billion of that total. EBITDA pre,
with which the earning power of operating activities is measured, climbed to
€ 3 billion.
Research and development spending amounted to € 1.5 billion. The operating
result totaled € 964 million and free cash flow was € 2 billion.
MERCK ONLINE:
SERVICE LINKS.
Important and current information on the company can be found on the Web at
www.merckgroup.com
The following websites offer information on special topics:
www.merckgroup.com/darmstadt, www.merckgroup.com/investors,
www.merckgroup.com/history, www.merckgroup.com/responsibility,
www.merckgroup.com/innovations
Up-to-date articles and reports on Merck, its fields of activity and products can be found at:
www.merckgroup.com/explorermagazine
Brochures and audiovisual media on Merck’s activities can be ordered from
Group Communications or downloaded from www.merckgroup.com/publications
3_013_FACTS+FIGURES_EN.indd 18
13.03.13 15:0

19. m
m
Se
r
ch
pm
Total revenues by division (in € million)
Merck Serono
6,405
M
erck Millipore
2,617
Performance Materials
1,676
Consumer Health
475
Operating result by division* (in € million)
Merck Serono
mm
508
M
erck Millipore
233
pm
ch
Ser
Performance Materials
599
Consumer Health
4
*excluding Corporate and Other
Sales by region (in € million)
N
orth America
2,128
Emerging Markets
3,712
EU
NA
Emerg Ma
3_013_FACTS+FIGURES_EN.indd 19
Rest
Europe
3,943
Rest of World
958
13.03.13 15:0

20. The Merck Group. An overview.
Published in March 2013
by Merck KGaA, Group Communications,
Frankfurter Strasse 250, 64293 Darmstadt, Germany
Phone: +49 (0) 6151-72 0
Fax: +49 (0) 6151-72 5577
E-mail: comms@merckgroup.com
Website: www.merckgroup.com
Photos: Robert Wilson, Torben Conrad
Concept and design: Nissen Carstensen GmbH
Lithography: data-graphis GmbH
Printing: Frotscher Druck GmbH, Darmstadt
W 840 103
3_013_FACTS+FIGURES_EN.indd 20
13.03.13 15:0